01 — At a Glance
The Chemistry of Crisis: A Company Caught Between Yesterday & Tomorrow
- 52-Week High / Low₹329 / ₹158
- Q3 FY26 Revenue₹416 Cr
- Q3 FY26 PAT₹-47 Cr
- TTM EPS₹-13.9
- 9M FY26 PAT₹-140 Cr
- Book Value / Share₹127
- Price to Book1.36x
- ROCE0.26%
- Debt (Sep 2025)₹2,086 Cr
- 3-Yr Stock CAGR-2.0%
Flash Summary: Thirumalai Chemicals is a tale of two companies. The old one — PAN manufacturing in India — is choking on bad spreads and margin pressure. The new one — a greenfield plant in West Virginia meant to produce higher-margin food acids and maleic anhydride — just started operations in Dec 2025, costing them ₹255 million (upgraded from ₹240 million), and won’t hit positive cash flow until maybe 2027-28. Meanwhile, the balance sheet shows debt at ₹2,086 crore and declining equity. ICRA downgraded them to BBB+ (Negative) in January 2026. The stock has crashed 44% in 6 months. And the management is betting everything on a company they’ve never run before, in a country they’ve never operated in, at a scale that’s absorbed their entire cash reserve.
02 — Introduction
The Slow-Motion Train Wreck That Chemistry Cannot Fix
Thirumalai Chemicals is not a startup. It’s been around since 1944 — when the Sampath family started a chemical trading house in Tamil Nadu. By the 1970s, they’d built a Phthalic Anhydride (PAN) facility in Ranipet that still runs today. They expanded into food acids in the 1990s, Malaysia in the 2000s, and in 2024 decided the logical next step was to build a ₹255-crore greenfield plant in West Virginia, USA. The stock price at the time? ₹329. Today? ₹171. That’s a 48% haircut in less than a year.
The company manufactures four main products: PAN (used for plasticizers and resins), Malic Acid (food and pharma), Fumaric Acid (food additives and inks), and Diethyl Phthalate (DEP, plasticizer). They ship to 60 countries and have customers like Reliance Industries (who supplies their raw material), Asian Paints, Parle, ITC, and Nerolac. On paper, this looks like a global chemicals powerhouse. In reality? The company lost ₹140 crores in nine months of FY26, is carrying ₹2,086 crores of debt, and the Malaysian facility is in the process of being divested because it’s bleeding cash. ICRA just dropped their rating by one full notch (from A- to BBB+) citing “weak PAN-OX spreads” and “liquidity stress.” Translation: they don’t have enough cash to service debt comfortably, and there’s no relief in sight.
The Merger & Acquisition Tea: In December 2025, the company closed a preferential allotment of 18,96,614 shares at ₹296 each, raising ₹56 crore from the promoter group. In other words: the family had to put their hand in their pocket to keep the company from running out of cash. That’s not a bullish signal. That’s triage.
03 — Business Model: Playing in a Commodity Casino
They Make Chemicals. You Use Them Every Day. And You’ll Never Know They Exist.
Members get full access to every article.
